391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials

Épidémiologie des tumeurs neuroendocrines intestinales

International audience; Few data are available about the epidemiology of digestive neuroendocrine tumours (NETs). Malignant digestive (MD) NETs remain as a rare cancer representing 1 % of digestive cancers. In France, the incidence rates of MD-NETs are estimated to around 1.1/100,000 inhabitants in males and 0.9/100,000 in females which then increased over time, with probably more than 1,000 new cases per year. Due to the relative good prognosis, NETs are the second more prevalent digestive cancer next to colorectal cancer. Most gastroenteropancreatic NETs are well-differentiated (WD-NETs); poorly differentiated neuroendocrine carcinomas (PDNEC) account for less than 20% of the cases in mos…

REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

International audience

Association Between Tumor Egfr and Kras Mutation Status and Clinical Outcomes in Nsclc Patients Randomized to Sorafenib Plus Best Supportive Care (BSC) or Bsc Alone: Subanalysis of the Phase III Mission Trial

ABSTRACT Background Tumor EGFR and KRas mutations are both predictive and prognostic biomarkers in patients with advanced NSCLC. We analyzed the correlation between these biomarkers and treatment outcomes in a phase III trial of 3rd/4th line sorafenib in patients with NSCLC. Methods The global, randomized, placebo-controlled MISSION trial enrolled 703 patients with advanced relapsed/refractory NSCLC of predominantly non-squamous histology. The primary study endpoint was overall survival (OS). EGFR and KRas mutations were analyzed in archival tumor samples and in circulating tumor DNA isolated from plasma. Results Tumor and/or plasma mutation data were available from 347 patients (49%). EGFR…

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

Abstract Purpose: There are conflicting results concerning the prognostic value of the CpG island methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this phenotype in stage III colon cancer characterized for mismatch repair (MMR), RAS, and BRAF status, and treated with adjuvant FOLFOX-based regimen. Experimental Design: Tumor samples of 1,907 patients enrolled in the PETACC-8 adjuvant phase III trial were analyzed. The method used was methylation-specific PCR, where CIMP+ status was defined by methylation of at least 3 of 5 following genes: IGF2, CACNA1G, NEUROG1, SOCS1, and RUNX3. Association between CIMP status and overall survival (OS), disease-free survi…